Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, DrPH, MBA, MPH, rose to Chief Public Health Officer while continuing as Senior Vice President and Practice Director for the evidence and strategy team, and these moves link brand strategies to public health in ways that equip life sciences, health plans, and providers with integrated strategies to enhance patient access, even as the US healthcare landscape remains complex.

These appointments show Avalere’s focus on targeting policy shifts like Medicare reforms, with key acts including the Affordable Care Act, the Bipartisan Budget Act of 2018, and the Inflation Reduction Act, while Kazan’s Capitol Hill and CMS expertise helps align with these changes, and Housman’s dual role stresses biopharma needs by syncing strategies with public health. Legislative changes affect manufacturer-patient ties and promote collaboration across teams, including policy, market access, evidence, value, and marketing, which turns uncertainties into opportunities and boosts patient reach.

These leadership changes may boost health economics and outcomes research (HEOR) at Avalere, aimed at anticipating IRA pricing pressures and CMS talks. It could also lead to accelerated real-world evidence generation needed for market access in ways that match PCORI priorities. Unified approaches (policy & public health strategies) may lead to improved patient outcomes by addressing payer demands and regulations. For more, check Avalere, details below.